Example collocations logo

Clinical in sentence

550 examples of Clinical in a sentence

The good news is that some progress is being made, with several vaccine clinical trials already underway.
Moreover, with support from the World Health Organization, at least one international platform for clinical trials has been created to assess the safety and efficacy of experimental Ebola treatments, as well as to establish scientific and ethical standards of care.
Running clinical trials under the auspices of affected countries’ health ministries and the WHO – with full transparency in terms of processes and outcomes – would enable the relevant authorities to make timely and informed decisions regarding which treatments and vaccines to investigate further and when to deploy them.
They must share with those at the front lines of the battle information about diseases’ natural history, modes of transmission, and risk factors, as well as preclinical data on – and clinical responses to – experimental treatments.
Of course, transparent clinical trials and open-data platforms raise legitimate ethical and intellectual-property concerns.
In the meantime, these concerns underscore the need for public-health officials to be involved in monitoring and coordinating clinical trials, and for improved information-sharing among experts and affected countries.
An open-data platform would facilitate discussion of the social value of clinical research and the associated ethical dilemmas.
These tests are now becoming part of clinical practice, and are available commercially.
Our focus now is on completing clinical trials for two promising new antimalarial drug candidates.
The clinical implications of the failure to recognize bipolar disorder in depressed patients include the under-prescription of mood-stabilizing medications, and an increased risk of rapid “cycling” – swings between manic and depressive phases.
But we think that an over-diagnosis rate of more than 50% crosses the clinical significance threshold.
Screening questionnaires maximize sensitivity, at a cost of false positives, because it is presumed that they are followed by expert clinical evaluation.
Already, studies to identify genes associated with common diseases – including some that represent significant health, economic, and social burdens, such as cancer, diabetes, cardiovascular disease, and obesity – are beginning to enable doctors to use patient DNA information to inform clinical care.
Even obesity may have connections to vitamin D. A clinical study found that providing supplements to obese and overweight people with vitamin D deficiency aids weight loss and enhances the benefits of a reduced-calorie diet.
We are still a few years away from clinical trials that explore the possible link between vitamin D supplements, higher vitamin D levels, and reduced risk of disease.
Genetic medicine is advancing at a rapid pace, but its clinical applications seem to be receding.
This language reflects the growing ability to transform human tissue into research materials and clinical products.
Research and clinical uses of body parts have been controversial since the early days of anatomical dissection, which once evoked Dante-esque visions of Hell.
Is this the Hollywood equivalent of a police officer’s “blue wall of silence,” or is there something more clinical at work?
Phase I clinical trials of the vaccine, sponsored and funded by the National Institute of Allergy and Infectious Diseases, began in February.
The institute’s researchers carry out innovative and complex science, from classic clinical trials and epidemiological studies to behavioral-modification trials aimed at reducing the spread of infectious disease – with remarkable results.
Three potential new treatments for malaria being developed by GSK (two in partnership with MMV) are progressing to clinical trials.
Another potential new drug being developed through a collaboration between GSK and MMV, for vivax malaria, is further along in the development process, having entered the final stages of clinical trials.
Another promising opportunity are investments in the riskiest stage of the development process for new drugs: the phase between basic research and human clinical trials, which has traditionally struggled to attract funding.
Indeed, for every $1 million dollars spent on this part of the process, some $8 million is spent on basic research and another $20 million on clinical trials.
We are now initiating clinical trials to determine how efficient these PARP inhibitors are in the treatment of metastasized breast tumors.
However, amniocentesis and CVS both entail a 0.5-1% risk of pregnancy loss, and if an abnormality is diagnosed the only clinical option is to terminate the pregnancy.
Ethicists have grappled with such scenarios, and many would find this clinical option to be ethically sound.
As my colleagues at the University of California, San Francisco, have reported, the Sugar Research Foundation – the industry’s trade group – even sought to persuade clinical medicine to focus on saturated fat instead of sugar, and pushed clinical dentistry to focus on a vaccine for tooth decay rather than sugar reduction.
Even among drugs that make it to human clinical trials, only one in five will clear that final hurdle.
Back